Results 91 to 100 of about 42,251 (222)

A Novel Approach for Glioblastoma Treatment by Combining Apoptosis Inducers (TMZ, MTX, and Cytarabine) with E.V.A. (Eltanexor, Venetoclax, and A1210477) Inhibiting XPO1, Bcl-2, and Mcl-1

Cells
Adjuvant treatment for Glioblastoma Grade 4 with Temozolomide (TMZ) inevitably fails due to therapeutic resistance, necessitating new approaches. Apoptosis induction in GB cells is inefficient, due to an excess of anti-apoptotic XPO1/Bcl-2-family ...
Kai Zhao, Madita Braun, Leonie Meyer, Katharina Otte, Hartmann Raifer, Frederik Helmprobst, Vincent Möschl, Axel Pagenstecher, Hans Urban, Michael W. Ronellenfitsch, Joachim P. Steinbach, Jelena Pesek, Bernhard Watzer, Wolfgang A. Nockher, R. Verena Taudte, Andreas Neubauer, Christopher Nimsky, Jörg W. Bartsch, Tillmann Rusch   +18 more
doaj   +1 more source

Risk of Acute Kidney Injury Associated With Nephrotoxic Burden in Hospitalized Patients: A Scoping Review

Clinical Pharmacology &Therapeutics, Volume 119, Issue 4, Page 891-904, April 2026.
Limited evidence exists synthesizing the risk of acute kidney injury (AKI) associated with the concomitant administration of multiple nephrotoxic drugs, and even less examining the concept of nephrotoxic burden. The objective of this scoping review was to (1) identify definitions of nephrotoxic burden; (2) methods used to quantify (use of calculations)
Wafa Alatawi, Jessica L. Wallace, Dhakrit Rungkitwattanakul, Britney A. Stottlemyer, Tiffany L. Tran, Melanie Manis Reida, Sandra L. Kane‐Gill   +6 more
wiley   +1 more source

Antiglioma effects of cytarabine on leptomeningeal metastasis of high-grade glioma by targeting the PI3K/Akt/mTOR pathway

Drug Design, Development and Therapy, 2017
Kai-Hong Zhao,1 Can Zhang,2 Yue Bai,1 Yan Li,1 Xun Kang,1 Jian-Xin Chen,1 Kun Yao,3 Tao Jiang,4 Xiao-Song Zhong,2 Wen-Bin Li1 1Department of Glioma, 2Clinical Center of Gene And Cell Engineering, Beijing Shijitan Hospital, 3Department of Neurosurgery ...
Zhao KH, Zhang C, Bai Y, Li Y, Kang X, Chen JX, Yao K, Jiang T, Zhong XS, Li WB   +9 more
doaj  

Disease progression more than 6 years after treatment impacts overall survival in mantle cell lymphoma

International Journal of Cancer, Volume 158, Issue 7, Page 1836-1845, 1 April 2026.
What's new? Patients with mantle cell lymphoma showing disease progression within 24 months of primary treatment have worse prognosis than patients with later progression. This population‐based study suggests that although early relapse is especially serious, disease progression more than 6 years after treatment still leads to worse survival than the ...
Sara Ekberg, Ingrid Glimelius, Alexandra Albertsson‐Lindblad, Karin E. Smedby, Mats Jerkeman, Caroline E. Dietrich   +5 more
wiley   +1 more source

Twenty Years of Therapeutic Leukocytapheresis in Newly Diagnosed Acute Myeloid Leukemia: Insights From A Single Center

Journal of Clinical Apheresis, Volume 41, Issue 2, April 2026.
ABSTRACT Acute myeloid leukemia (AML) is a heterogeneous hematologic malignancy, and 5%–20% of newly diagnosed patients present with hyperleukocytosis (HL). HL, most often defined as WBC > 100 000/μL, is a hematologic emergency associated with severe complications, early mortality, and poor prognosis, requiring immediate intervention.
Vojtech Latal, Ivana Skoumalova, Miroslava Palova, Tomas Szotkowski, Martin Cernan, Jana Navratilova, Helena Urbankova, Zuzana Pikalova, Ludek Raida, Edgar Faber, Tomas Papajik   +10 more
wiley   +1 more source

Chronic Myeloid Leukemia Presenting With T‐Lymphoid Blast Crisis in a Young Female With Marked Hyperleukocytosis: A Case Report

eJHaem, Volume 7, Issue 2, April 2026.
Abstract Background Chronic myeloid leukemia (CML) presenting in blast crisis (BC) is uncommon in the era of tyrosine kinase inhibitor (TKI) treatment, and T‐lymphoblastic BC is exceptionally rare. We report a case of T‐lymphoid BC presenting with extreme hyperleukocytosis.
E. Somasundaram, R. P. Hasserjian, B. J. Aubrey, A. T. Fathi, H. Hock   +4 more
wiley   +1 more source

Haploidentical Hematopoietic Stem Cell Transplantation With Anti‐Thymocyte Globulin in the Treatment of Older Adults With Hematological Malignancy

eJHaem, Volume 7, Issue 2, April 2026.
ABSTRACT Objectives Studies on the efficacy and safety of haploidentical hematopoietic stem cell transplantation (haplo‐SCT) with anti‐thymocyte globulin (ATG) in patients aged ≥ 60 years remain limited. Methods We performed a study presenting data from 54 patients aged ≥ 60 years with hematologic malignancies who underwent haplo‐SCT with ATG.
Xin Kong, Jingjing Han, Yin Liu, Baoquan Song, Xiaowen Tang, Shengli Xue, Miao Miao, Yue Han, Ying Wang, Suning Chen, Aining Sun, Mingming Hu, Jun Chen, Feng Chen, Jian Zhang, Hui‐Ying Qiu, Depei Wu   +16 more
wiley   +1 more source

Real‐World Analysis of Outcomes of Venetoclax+Azacitidine Versus 7+3 Induction in Acute Myeloid Leukemia

eJHaem, Volume 7, Issue 2, April 2026.
ABSTRACT Background Venetoclax plus azacitidine (V+A) is standard for older, intensive‐ineligible patients with acute myeloid leukemia (AML). Its expanding use in younger, curative‐eligible adults lacks comparative evidence against conventional 7+3 induction, raising uncertainty about potential survival compromise.
Nehemias Guevara Rodriguez, Noemy Coreas Mercado, Syeda Ashna Fatima Kamal, Sandeep Beesabathina, Dawson Foster, Nabeel Rajeh, Ranju Kunwor   +6 more
wiley   +1 more source

Identification of an Elusive CBFA2T3::GLIS2 Fusion Variant in Acute Megakaryoblastic Leukemia by Whole Genome Sequencing

eJHaem, Volume 7, Issue 2, April 2026.
ABSTRACT Advancements in genomic profiling have significantly improved the classification and treatment strategies for acute myeloid leukemia (AML). However, widely utilized molecular diagnostic techniques, including targeted gene panels, are often insufficient for detecting complex structural variants, cryptic fusions, and poorly characterized driver ...
Yuna Lee, Jung Yoon Choi, Hyun Jin Park, Bo Kyung Kim, Hyun Kyung Kim, Yeseul Kim, Jung‐Eun Cheon, Sung‐Hye Park, Ji Hoon Phi, Ji Won Lee, Ryul Kim, June‐Young Koh, Hyoung Jin Kang   +12 more
wiley   +1 more source

Identification of a Novel, Oncogenic and Targetable TPR::ABL2 Fusion Gene in T‐Cell Acute Lymphoblastic Leukaemia

eJHaem, Volume 7, Issue 2, April 2026.
ABSTRACT ABL2 rearrangements represent a subtype of acute lymphoblastic leukaemia (ALL) associated with poor prognosis and survival. This study reports a high‐risk T‐cell ALL (T‐ALL) case with a novel TPR::ABL2 gene fusion resulting from a chromosomal deletion.
Elias Lagonik, Elyse. C. Page, Laura N. Eadie, Caitlin E. Schutz, Jacqueline A. Rehn, Susan L. Heatley, Andrew S. Moore, Muirin Healy, Morag Whyte, Timothy P. Hughes, David T. Yeung, Deborah L. White   +11 more
wiley   +1 more source